Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10721619 | 0.87 | SLC1A1 (0.50) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL10954741 | 0.83 | SLC1A1 (0.45) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL2648222 | 0.80 | SLC1A1 (0.49) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL7518962 | 0.80 | SLC1A1 (0.56) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL7440229 | 0.80 | SLC1A1 (0.65) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL8444795 | 0.79 | PPID (0.42) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL27857317 | 0.79 | FOLH1 (0.58) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL11635275 | 0.79 | CNR2 (0.54) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL5370668 | 0.78 | SLC1A1 (0.50) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 | |
| SCHEMBL5370656 | 0.78 | SLC1A1 (0.50) | SLC1A1KMT2ASLC1A3SLC1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724278-B1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7998975-B2 | Sodium dependent glucose transporter inhibition; hyperglycemia associated diseases; 3-glucopyranosyloxy- 1H-indazole and 1H-pyrazolo[3,4-b]pyridine derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20080188426-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7375113-B2 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1724278-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | SLC5A1, SLC5A2, GPR119 | SLC1A1 257/4885KMT2A 905/4885SLC1A3 271/4885 |
| US-20080188426-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | SLC5A1, SLC5A2, SLC2A1 | SLC1A1 274/4885KMT2A 699/4885SLC1A3 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.